µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ CiLg]va
[<6^qla
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ VfC <WVYiZ
][h%UrV
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ &LZn
FR
as4;:
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© s6v;
Jg\zdi:t
1. CD4 )SRefW
.v
L<-_1!wh
2. T cell receptor(TCR) \[_t]'p
'(yAfL 9}
3. immunoglobulin superfamily (IgSF) -)]Yr #Q
L Mbn
4. selectin [-k
(%e.:W${
5. anti-idiotypic antibody (¦ÁId) ?2;&O`x*
q`H_M{26!y
6. major histocompatibility complex(MHC) ith
3=`3
.4M.y:F
7. immunotolerance &5spTMw8
&<5zqsNJ\a
8. biological reponse modifier(BRM) QP^Cx=
ceh j;
9. immune reponse gene (Ir gene) \y)rt )
% X+:o]T
10. reshaped antibody (or reconstituted antibody) ~u
!|qM
_8riUt
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© zyc"]IzOU
o]` *M|
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ KL:j?.0
KRLQ #,9
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? udF~5w
H
<fjX[l<Uz
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ Z!#!Gu*V
-p&" y3<p
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? k\YG^I
*_{j=sd
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) *{@Nq=fE
P
*Uwg&Qz)
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ GT!M[*[
/y#f3r+*2
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? fue(
UMF~
dA`IEQJL
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? } FlT%>Gw
%lx!.G
¡¡ uk]$#TV*q>
+I:Unp
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ C12
Fl
eKLZt%=
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? m
3hrb-
c|B('3h
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? 4 Y9`IgQ
|`,2ri*5A
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ufZDF=$7
j'<<4.(
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ x0D*U?A
)0W{]2
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ m@F`!qY~Y\
T_
<@..C
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© #PW9:_BE
]BZA:dd.G
1. CD8 &|ex`nwc0
l
-m fFN
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) :$|HNeDO
;_I8^? d
3. immunoglobulin fold(Ig fold) EIAc@
$4
8)3*6+D
4. cadherin (Ca-dependent cell adhesion moleculers) EhvX)s
7wqK>Y1a
5. idiotype-anti-idiotypic antibody immune network theory ^_W#+>&--
1Z2HUzqh.
6. HLA class II antigen A#<? 4&
cn3
\kT*
7. complementarity-determining region (CDR) rJTa
$dC?Tl|B0
8. perforin(or pore-forming protein ,PFP)
QXFo1m
`?@}>.
9. high affinity IL-2 receptor 2(+2+}
1#2
I
10. artificial active immunization (gU!=F?#m
xml7Uarc
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© m,w A:o$'
}?i0
I
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠM h}m;NI
3M7/?TMw{6
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 uyWunpT
gPO}d
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ U_Ptqqt%
P4'Q/Sj
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ p)-^;=<B3
&h)yro
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1(R}tRR7 R
/-'}q=M
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ #p&qUw
[l??A
3G
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? &PHTpkaam
|SSSH
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ J!(<y(l
.2t4tb(SUw
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ U< fGGCw
)2o?#8J
¡¡ pah'>dAL
J*A,o~U|
C.-,^+t;g
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Q3~H{)[Kq
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ 2l'6.
vI>w e
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ (5YM?QAd
F/
{!tx
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© qe#tj/aZ
M|h3Wt~7
1. immunoglobulin gene rearrangement \gaw6S>n}
Bsvr?|L\
2. the common chain of cytokine receptor (or a cytokine receptor uGG t\.$]s
(?c"$|^J
subunit shared by some cytokine receptors) 7n<{tM
f8dB-FlMm
3. flow cytometry(FCM) DyQy^G'%l
<%eG:n,#
4. carrier effect d7upz]K9g
/([kh~a
5. positive selection of T lymphocytes in thymus #;yZ
6bC3O4Rw
6. mouse TH1(Th1) and TH2(Th2) subsets ?fSG'\h>
*g2x%aZWbG
7. perforin (pore-forming protein ,PFP) d$!RZHo10V
_Fl9>C"u
8. ADCC(antibody-dependent cell-mediated cytotoxicity) )ez9"# MH'
)Aqtew+A&
9. SH-2(src-homology region 2) 7{*>agQh
f+!(k)GWd
10. Ab2¦Â (internal image) F JyT+
(!WD1w
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Iefn$
YOO+R{4(
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? x%B/
4kx
N<]
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? j\M?~=*w
L
!xi
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠgcT%c|.
RA
L~!"W
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ lThB2/tV\
OneY_<*a<
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠJ|7 3.&B
&};zvo~P.
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) X&H"51
W"{N Bi
ÃâÒßѧרҵ£º Z%UP6%
8}:nGK|kx
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ `R^g U]Z,
)^hbsMhO
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? J{G?-+`
seJ^s@H5l
´«È¾²¡Ñ§×¨Òµ£º :ShT|n7
8
z\xrY
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ #/37V2E
F!K>K z
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ Wd
ELV3
U6s[`H3I{
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ `Pnoxm'
dj%!I:Q>u
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? #g!.T g'
_q^E,P
X}0cCdW
yB6?`3A:
3G4-^hY<
?Mfw]z"\C)
/qw.p#
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 1h5 Akq
T51
`oZ`
ÃâÒßѧÊÔÌâ Rf1x`wml
fF kj+
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© +ck}l2
bZV/l4TU
1. Fas(CD95)/FasL *{{89E>wC
9nbLg5P
2. common chain of cytokine receptor 3R VR
rrv%~giU
3 . TCR/CD3 complex rVsJ`+L
Y6d@h? ht
4. negaive selection of thymocytes 0ZO2#>gh$
lw5`p,`
5. artificial active immune ReeH@.74
g=o4Q<
#^y
6. anti-idiotypic v*yuE5{
h)nG)|c
7. IgSF FxtI"g\0
VLN_w$iEq
8. Integrin G*v,GR
c[Zje7 @
9. chemokine ^G-@06 /!
4xJQ!>6
10. B7/CD28 tklH@'q
/H+a0`/
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© +d-NL?c
jlg(drTo
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ H 7
^/q7
y18Y:)DkL
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ KCDE{za
gv{ >`AN
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ ^y4Z+Gu[
.XhrCiZ
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ Ld-_,-n
o
,3a4nH;
uA#;G/$
ymcLFRu
,
y L~W.H
~.lPEA %%
vgN&K@hJ
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ w"&n?L
@gXx1hEg
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© r-/`"j{O!
]:/Q]n^
1. B7/CD28 63x?MY6
yJe>JK~)
2. Th1 subset c-FcEW
8|58 H
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© eO[b1]WLP
@2v_pJy^
4. antibody affinity maturation IRqy%@)
VBcPu
5. AP-1 `,*5wBC
#
c^z&0B}
6. single chain variable fragment£¨ScFv£© 0NX,QD
l0i^uMS
7. NK cell receptor D*|Bb
?
07=mj%yV
8. Zinkernagel-Doherty phenomenon x`)&J
B
SGlNKA},A
9. Ig fold 3>VL}Ui}
YLn?.sV{[0
10. CD40/CD40L i&GH/y
UU0,!?o4
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© x{WD;$J
fPW@{~t
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ -_eLf#3
mUF,@>o
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ <B8!.|19
e.V:)7Uc
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
k7A-J\
yd`mG{Z
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ y;@:ulv[
=
6\ ^%
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ e(=w(;84
scLll ,~
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ H\tUpan6fy
,^f+^^
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ l$bu%SZ
xbYi.
agW@{c
?zHPJLv|Y
>%8KK|V{
H-f X(9
a ]tVd#
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ Q9G;V]./
qE3UO<FA
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© SPmq4
O2dW6bt
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© u-G+ j)
yT9@!]^L
1.Co-stimulators (or co-stimulating molecules) D#JL!A%O
:mn>0jK,N
2.NK-kB $F
+ L Ds
A*P|
e-&Q8
3.Immunoglobulin superfamily !6>~?gNd
\WB<86+z
4.antigen-presenting cell (APC) @;?p&.W`D
|kV*Jc k
5.death domain Zu("#cA.H
$#pPZ
6.CCR and CXCR [o+q>|q
.Cl:eu,]
7.Lectin (or mitogen) ?8Z0Gqt74
?FF4zI~
8.Clusters of differentiation, CD) mtmjZP(w
3L}!RB
9.B7 family k=JrLfD4
Jx](G>F4f1
10.Cytotoxic T lymphocyte, CTL) 8sM|%<$=j
(UvM@]B
11.IL-15 and IL-15 receptor (IL-15R) Q&=w_Wc
,UGRrS
12.MHC restriction bITPQ7+
;=;
9tX
13.Affinity-chromatography IIF]/
Ek]
Cdu4U}^H
14.Cyctosprin A, CsA vMt/u?oB
v|%Z+w
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) e2t-4}
ww
``Dq
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 9c#+qH
#W'H
R
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 1
&)?JZhg
]?+p5;{y4
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ bM!_e3ik;
sRx63{
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ n}_JB
>i~
dWUm\t'#
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© _w/EP
q[`]D7W
"
ÃâÒßѧרҵ£º vCxD~+zf
, 5kKimTt
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ (\a]"g,]v
Iw&vTU=2
Ïû»¯ÄÚ¿Æ£º EQ`(yj
xtE_=5$~
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ !*m5F8Qm?A
^ZhG>L*
ѪҺ²¡Ñ§×¨Òµ£º (m.ob+D
XKttZOiGT
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ Ib\iT:AJ
L
ugn3+
AW_(T\P:u
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 04'~ta(t
"
'6;/N
(רҵ»ù´¡: ÃâÒßѧ) |8=nL$u
_$f9]bab
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) gu<'QV"
< hO
/jB
1. ADCC(antibody dependent cell-mediated cytotoxicity) x~{;TZa[I
{%{`l-
2. »·æß¾úËØ(cyclosporin) gk+h8 LZ
9h%?QC
3. KIR(killer cell inhibitory receptor) J-)
XQDD
t{FlB!jv
4. HLDA(human leucocyte differentiation antigen) 8&~~j7p,
\ZhfgE8{%
5. Interleukin 18(IL-18) z$GoaS(
IWveW8qJ
6. ÕûºÏËØ(integrin) 4RV%Z!kcD!
`|#Qx3n%
7. Fas/FasL iMFgmM|
E}_[QEY;Y
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) GbA.UM~
MR,R}B$
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) r"a5(Q;n
+1!qs,
10. Th1/Th2
-zO2|@S,
"/6:6`J
11. »ùÒòÒßÃç(DNAÒßÃç) C?= P
?N=m<fn
12. chemokines and chemokine receptor 1q3(
@D5~+
-0eq_+oQ
13. ÃâÒßÄÍÊÜ V &|Ed
E)-r+ <l
14. ¹²´Ì¼¤·Ö×Ó 0lsXCr_X
-:9P%jWt
15. ËÀÍö½á¹¹Óò(death domain) W$o27f
#9fWAF
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 1s*.A6EP"
@a>2c$%
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? @@g\2
Gs
ror|R@;y
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠHb(B?!M)
6vTo*8D
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î "ZHtR/;
9Sq%s
&
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ <U9/InN0[
-/dEsgO
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå oM1
6C|
cZ+7.oDu
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ sz):oea@f@
\mN[gT}LHm
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£